KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Profit After Tax (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Profit After Tax for 16 consecutive years, with -$141.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 203.37% to -$141.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $316.9 million, a 28.64% decrease, with the full-year FY2025 number at $316.9 million, down 28.64% from a year prior.
  • Profit After Tax was -$141.6 million for Q4 2025 at Halozyme Therapeutics, down from $175.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $216.6 million in Q3 2021 to a low of -$141.6 million in Q4 2025.
  • A 5-year average of $82.4 million and a median of $79.3 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: surged 557.07% in 2021, then tumbled 203.37% in 2025.
  • Halozyme Therapeutics' Profit After Tax stood at $66.8 million in 2021, then decreased by 13.58% to $57.7 million in 2022, then surged by 47.98% to $85.4 million in 2023, then surged by 60.46% to $137.0 million in 2024, then crashed by 203.37% to -$141.6 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Profit After Tax are -$141.6 million (Q4 2025), $175.3 million (Q3 2025), and $165.1 million (Q2 2025).